RLT
Radioligand therapy prostate-specific membrane antigen
Advertisement
Dr. Tagawa explains the rationale for EVOLUTION, a phase II analysis of Lu-PSMA-617 with ipilimumab and nivolumab in mCRPC.
Dr. Tagawa contextualizes a post hoc analysis on clonal hematopoiesis in those who received 177Lu-PSMA-617 or cabazitaxel.
Dr. Tagawa showcases the ProstACT Global trial, a phase III study of 177Lu-rosptamab in patients with mCRPC.
Dr. Tagawa breaks down the VIOLET study, a single-arm phase I/II first-in-human results of terbium-161Tb-PSMA-I&T.
Dr. Ozay discusses her study that compared the efficacy of cabazitaxel with lutetium Lu-177 in patients with mCRPC.
Drs. Privé and Tagawa discuss the BULLSEYE trial, an analysis of Lutetium-177-PSMA-617 in oligometastatic HSPC.
Louise Emmett, MD, discusses the ENZA-p trial which studied enzalutamide versus enzalutamide plus [177Lu] Lu-PSMA-617.
The addition of ipi/nivo to LuPSMA improved PSA-PFS over 12 months in patients with mCRPC.
18F-flotufolastat-PET can help determine severe hematologic toxicity in patients with mCRPC who are treated with 177Lu.
Dr. Tagawa compares the use of PSMA-targeted antibodies to other treatment approaches such as radioligand therapy.
Dr. Kishan reviews current evidence supporting the use of PSMA RLT in patients with oligometastatic disease.
177Lu vipivotide tetraxetan is the only PSMA-targeted agent to significantly improve rPFS with a tolerable safety profile.
Dr. Morris discusses trials and rationale behind using PSMA therapy earlier in prostate cancer treatment.
Dr. Hofman outlines promising PSMA combination therapies and emerging trials aiming to improve prostate cancer outcomes.
Dr. Calais provides an overview of this year's PSMA and Beyond conference agenda.
Enzalutamide with [177Lu]Lu-PSMA-617 improved OS and HRQOL, along with PSA PFS.
Patients with BRCA mutations had a higher risk of death, while patients with PTEN/TP53/RB1 mutations did not.
Dr. Sartor offers insight on the efficacy of 177Lu-PSMA-617 in prolonging progression-free survival rates.
In part five of this roundtable series, the panelists discuss radiopharmaceuticals in the overall landscape of mCRPC.
The panel discusses the emerging field of PSMA-targeted alpha radioligand therapy, with a focus on HK2.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.